ALDXAldeyra Therapeutics Inc
ALDX
Aldeyra Therapeutics Inc8,456
Mkt Cap
$108.93MVolume
29,015.0052W High
$6.8152W Low
$1.07PE Ratio
-3.21ALDX Fundamentals
Price
$1.81Prev Close
$1.83Open
$1.9350D MA
$4.74Beta
2.73Avg. Volume
756,258.67EPS (Annual)
-$0.5636P/B
2.46Rev/Employee
$0.00$256.58
Richard Douglas Purchases 70,000 Shares of Aldeyra Therapeutics (NASDAQ:ALDX) Stock
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Get Free Report) Director Richard Douglas purchased 70,000 shares of the stock in a transaction that occurred on Thursday, March 19th. The stock was acquired at an average cost of $1.40 per share, with a total value of $98,000.00. Following the acquisition...
MarketBeat·2d ago
Wall Street Zen Downgrades Aldeyra Therapeutics (NASDAQ:ALDX) to Sell
Wall Street Zen cut shares of Aldeyra Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat·2d ago
Insider Buying: Aldeyra Therapeutics (NASDAQ:ALDX) Director Purchases 70,000 Shares of Stock
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Get Free Report) Director Richard Douglas purchased 70,000 shares of the business's stock in a transaction on Thursday, March 19th. The shares were purchased at an average price of $1.40 per share, with a total value of $98,000.00. Following the completion...
MarketBeat·2d ago
Rosen Law Firm Encourages Aldeyra Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation ALDX
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) resulting from...
Business Wire·2d ago
What is HC Wainwright's Forecast for ALDX FY2026 Earnings?
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Free Report) - Analysts at HC Wainwright dropped their FY2026 earnings per share (EPS) estimates for Aldeyra Therapeutics in a research note issued to investors on Wednesday, March 18th. HC Wainwright analyst M. Caufield now expects that the biotechnology co...
MarketBeat·3d ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...
PR Newswire·3d ago
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval Prospects: Levi & Korsinsky
ALDX Investor Alert: Aldeyra Therapeutics, Inc. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Management Allegedly Misrepresented Drug Efficacy And Approval...
PR Newswire·5d ago
ALDX Crashes 71% as FDA Issues Third CRL for Dry Eye Disease Drug NDA
Aldeyra Therapeutics stock plunges 71% after the FDA issues a third CRL for the resubmitted reproxalap NDA for the treatment of dry eye disease.
Zacks·5d ago
Aldeyra Therapeutics (NASDAQ:ALDX) Given "Neutral" Rating at HC Wainwright
HC Wainwright reiterated a "neutral" rating and issued a $2.00 price target (down from $10.00) on shares of Aldeyra Therapeutics in a report on Wednesday...
MarketBeat·5d ago
Aldeyra Therapeutics Sees Unusually High Options Volume (NASDAQ:ALDX)
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX - Get Free Report) was the target of some unusual options trading activity on Tuesday. Stock traders purchased 31,566 put options on the company. This is an...
MarketBeat·6d ago
<
1
2
...
>